Fax: (713) 794-5664
Article first published online: 28 JUN 2011
Copyright © 2011 American Cancer Society
Volume 117, Issue 24, pages 5476–5484, 15 December 2011
How to Cite
Gong, Y., Huo, L., Liu, P., Sneige, N., Sun, X., Ueno, N. T., Lucci, A., Buchholz, T. A., Valero, V. and Cristofanilli, M. (2011), Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer, 117: 5476–5484. doi: 10.1002/cncr.26179
Presented at the 99th Annual Meeting of the United States and Canadian Academy of Pathology, Washington, DC, March 20-26, 2010.
We thank Karen Muller in the Department of Scientific Publications at The University of Texas MD Anderson Cancer Center for editing this article.
- Issue published online: 2 DEC 2011
- Article first published online: 28 JUN 2011
- Manuscript Accepted: 14 MAR 2011
- Manuscript Revised: 17 FEB 2011
- Manuscript Received: 21 JAN 2011
- inflammatory breast cancer;
- enhancer of zeste homolog 2;
- estrogen receptor;
- human epidermal growth factor receptor 2;
Enhancer of zeste homolog 2 (EZH2), a member of polycomb group proteins, is involved in the regulation of cell cycle progression and has been implicated in various human malignancies, including breast cancer, and also has been associated with aggressive tumor behavior. However, the clinical significance of EZH2 expression in inflammatory breast cancer (IBC), a rare but aggressive type of breast carcinoma, has not been explored. In this retrospective study, the authors examined EZH2 expression in IBC tumors and evaluated the relation between EZH2 expression and patient survival.
Tissue microarrays of 88 surgically resected IBC tumors were stained immunohistochemically for EZH2, and the authors evaluated the association of EZH2 expression status with clinicopathologic factors and clinical outcome.
The median follow-up for the entire cohort was 45.7 months, and the 5-year overall survival (OS) rate was 45%. EZH2 was expressed frequently in IBC tumors (75.7%) and was associated significantly with unfavorable prognostic factors, such as higher tumor grade, negative estrogen receptor status, and triple-negative status (ie, negative for the estrogen, progesterone, and human epidermal growth factor 2 receptors). Univariate survival analysis indicated that patients who had EZH2-positive IBC had a significantly lower 5-year OS rate than patients who had EZH2-negative IBC (P = .01). In multivariate analysis, only positive EZH2 status remained an independent predictor of worse OS.
EZH2 was expressed frequently in IBC tumors. The current results indicated that EZH2 expression status may be used to identify a subset of patients with IBC who have a relatively worse prognosis. Targeting EZH2 also may provide a novel strategy for improving the clinical outcome of patients with IBC. Cancer 2011;. © 2011 American Cancer Society.